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Abstract
Aims/hypothesis As part of the Surrogate Markers for Micro- and Macrovascular Hard Endpoints for Innovative Diabetes Tools
(SUMMIT) programme we previously reported that large panels of biomarkers derived from three analytical platforms
maximised prediction of progression of renal decline in type 2 diabetes. Here, we hypothesised that smaller (n ≤ 5), platform-
specific combinations of biomarkers selected from these larger panels might achieve similar prediction performance when tested
in three additional type 2 diabetes cohorts.
Methods We used 657 serum samples, held under differing storage conditions, from the Scania Diabetes Registry (SDR) and
Genetics of Diabetes Audit and Research Tayside (GoDARTS), and a further 183 nested case–control sample set from the
Collaborative Atorvastatin in Diabetes Study (CARDS). We analysed 42 biomarkers measured on the SDR and GoDARTS
samples by a variety of methods including standard ELISA, multiplexed ELISA (Luminex) and mass spectrometry. The subset of
21 Luminex biomarkers was also measured on the CARDS samples. We used the event definition of loss of >20% of baseline
eGFR during follow-up from a baseline eGFR of 30–75 ml min−1 [1.73 m]−2. A total of 403 individuals experienced an event
during a median follow-up of 7 years. We used discrete-time logistic regression models with tenfold cross-validation to assess
association of biomarker panels with loss of kidney function.
Results Twelve biomarkers showed significant association with eGFR decline adjusted for covariates in one or more of the
sample sets when evaluated singly. Kidney injury molecule 1 (KIM-1) and β2-microglobulin (B2M) showed the most consistent
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effects, with standardised odds ratios for progression of at least 1.4 (p < 0.0003) in all cohorts. A combination of B2M and KIM-1
added to clinical covariates, including baseline eGFR and albuminuria, modestly improved prediction, increasing the area under
the curve in the SDR, Go-DARTS and CARDS by 0.079, 0.073 and 0.239, respectively. Neither the inclusion of additional
Luminex biomarkers on top of B2M and KIM-1 nor a sparse mass spectrometry panel, nor the larger multiplatform panels
previously identified, consistently improved prediction further across all validation sets.
Conclusions/interpretation Serum KIM-1 and B2M independently improve prediction of renal decline from an eGFR of 30–
75 ml min−1 [1.73 m]−2 in type 2 diabetes beyond clinical factors and prior eGFR and are robust to varying sample storage
conditions. Larger panels of biomarkers did not improve prediction beyond these two biomarkers.
Keywords Clinical science . Epidemiology . Nephropathy . Proteomics/metabolomics
Abbreviations
ADMA Asymmetric dimethylarginine
AUROC Area under the receiver operator
characteristic curve
B2M β2-Microglobulin
CARDS Collaborative Atorvastatin Diabetes Study
CKD Chronic kidney disease
CVD Cardiovascular disease
GoDARTS Genetics of Diabetes Audit and Research
in Tayside
IL2Ra IL-2 receptor α
KIM-1 Kidney injury molecule 1
NT-proBNP N-terminal prohormone of brain natriuretic
peptide
SDMA Symmetric dimethylarginine
SDR Scania Diabetes Registry
SUMMIT Surrogate Markers for Micro- and
Macrovascular Hard Endpoints for
Innovative Diabetes Tools
Introduction
Development of biomarkers predictive of renal disease pro-
gression in diabetes would enable enrichment of clinical trials
with individuals most at risk [1]. However, the majority of
renal biomarker studies have focused on a single biomarker
at a time rather than evaluating the potential of large sets of
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candidates or high-dimensional arrays such as metabolomics
panels [2–5].
As part of the Surrogate Markers for Micro- and
Macrovascular Hard Endpoints for Innovative Diabetes
Tools (SUMMIT) programme http://www.imi-summit.eu/,
we previously undertook a nested case–control study in
people with type 2 diabetes and chronic kidney disease
(CKD; stage 3) at baseline. Therein we identified, from
across 207 biomarkers measured by several platforms, which
subset maximised prediction of progression in renal function
decline on top of both a sparse and an extensive set of clinical
covariates [6]. Using forward selection and least absolute
shrinkage and selection operator (LASSO) penalised regres-
sion approaches, we identified biomarker panels that
maximised prediction. Altogether, 42 biomarkers were
contained in the two panels we identified using these two
approaches.
Since smaller sets of biomarkers that only require a single
platform or assay method would be cheaper and more logisti-
cally feasible to implement, it is important to consider the
extent to which such sparser sets can yield similar gains in
prediction to those achieved by large panels found by
maximising predictive performance. It is also important to
assess whether biomarkers are robust to different biosampling
storage conditions, as in our original study all samples had
been stored at −80°C. Accordingly, starting with the 42 bio-
markers from the previously selected panels we first generated
sparse panels of the top five biomarkers from each of the mass
spectrometry and then the ELISA/Luminex platforms, respec-
tively, in the original nested case–control study data. Next, we
tested the hypothesis that these smaller (n ≤ 5), platform-
specific combinations might achieve prediction performance
similar to that of the larger panels. Specifically, we assessed
the performance of these smaller panels, and their subsets, for
predicting renal disease progression in three new sample sets
that were collected under different sampling and storage con-
ditions and from type 2 diabetes cohorts with different clinical
characteristics.
Methods
Study populations The original study was a case–control de-
sign nested in the Genetics of Diabetes Audit and Research in
Tayside (GoDARTS) cohort, a hospital clinic- and primary
care-based cohort of people with diabetes in the Tayside re-
gion of Scotland [7]. Here, we also used samples from indi-
viduals in GoDARTS who had not been included in the orig-
inal case–control study and also used an independent set of
samples from the Swedish Scania Diabetes Registry (SDR)
cohort [8]. For both cohorts, biosamples were collected at
the time of study enrolment and were stored according to
study-specific protocols [7, 8]. In addition, we used samples
from a clinical trial of atorvastatin in people with type 2 dia-
betes whose eGFR had been measured during follow-up (the
Collaborative Atorvastatin in Diabetes Study [CARDS],
ClinicalTrial.gov registration no. NCT00327418) [9].
Phenotype In the original study [6] we evaluated the perfor-
mance of biomarkers to predict rapid progression of eGFR
defined as ≥40% loss of baseline eGFR within 3.5 years with
entrants having a baseline eGFR (calculated by the MDRD4
equation) [10] of 30–60 ml min−1 [1.73 m]−2 (i.e. CKD3) [6].
Here, we broadened the inclusion criteria to include people
with less renal dysfunction at baseline (eGFR 30–75 ml min−1
[1.73 m]−2) since this range of eGFR is often used for trial
entry criteria. Among all participants with this baseline eGFR
in these cohorts we compared the ability of biomarkers to
predict being a progressor—defined as at least two measures
of an eGFR with a > 20% drop from baseline sustained for at
least 1 month at any time during follow-up, but within
6 months of each other. Thus, compared with the original
study, we are evaluating the biomarkers’ ability to predict a
more subtle decline in renal function.
In CARDS, entrants also had a baseline eGFR of 30–
75 ml min−1 [1.73 m]−2, with cases also having had a loss
>20% of baseline eGFR during follow-up. However, rather
than including all non-cases as for SDR and GoDARTS,
control participants were randomly selected from individuals
who did not lose >20% of baseline eGFR matched to cases
based on baseline eGFR (strata 30–60 and 60–75 ml min−1
[1.73 m]−2), age (5 year bands) and sex. We used this nested
case–control design in CARDS as we had insufficient funds to
measure all CARDS samples.
Clinical covariatesClinical covariates from the time of sampling
were taken from the study-specific databases. HbA1c and serum
creatinine were measured as part of clinical care using standard
methods. Albuminuria was assessed by either a urinary albumin
concentration on a spot urine or a 24 h urinary protein concen-
tration with albuminuria status based on the highest level of
albuminuria (normo-, micro- or macroalbuminuria) recorded
in the 5 years prior to baseline. Smoking status was based on
self-report. Medication data was available from the GoDARTS
cohort based on primary care prescribing data and from the
CARDS study from self-report at enrolment.
Laboratory measurement of biomarkers We measured a total
of 42 biomarkers and biomarker ratios that had been included
in the large panels generated from the initial SUMMIT study.
ELISAs were used for high-sensitivity troponin T using the
Roche assay at the University Heart Center Hamburg bio-
marker laboratory. Multiplexed ELISAs using Luminex tech-
nology were used to perform multiplexed, microsphere-based
assays for 20 biomarkers as described [11] at the CLIA certi-
fied Myriad RBM laboratory (Austin, TX, USA) (see
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electronic supplementary material [ESM] Methods). Liquid
chromatography (LC) electrospray tandemmass spectrometry
(MSMS) platforms for targeted metabolite and tryptic peptide
analyses were used to measure the remaining 20 biomarkers at
the WellChild Laboratory (Kings College London, UK). The
ratio of asymmetric dimethylarginine (ADMA) to symmetric
dimethylarginine (SDMA) was determined. For GoDARTS
and SDR samples all biomarkers were available but for the
CARDS samples for budgetary reasons we only measured the
Luminex platform biomarkers. Details of the biomarkers and
their distribution in the study samples are shown in ESM
Table 1. For further details of methods and sample quality
control data for the biomarkers measured, see ESM Methods.
Biomarker data cleaning and imputation The data from the
biomarker laboratories were cleaned and imputed using a
sparse iterative regression model before analysis. The iterative
imputation model was run ten times, with initial values of the
missing at random entries set by sampling from the marginal
distribution of the observed values for each variable (see ESM
Methods). The dataset used in analysis was the average of the
ten imputed sets. All data were Gaussianised prior to analysis
by rank transforming each continuous variable and mapping
ranks to quantiles of a normal distribution. Generally for al-
most all biomarkers few samples had undetectable levels or
had missing data for other reasons (see ESM Table 1).
Univariate associations of biomarkers with renal disease pro-
gression We first described univariate associations of the 42
biomarkers being considered with renal disease progression in
the three datasets (SDR, GoDARTS and CARDS) separately.
Significance was declared at p < 0.0012 based on Bonferroni
adjustment. Follow-up was partitioned into 1 year time win-
dows with calendar time included in all models as a linear
term. We used discrete-time logistic regression models to de-
scribe associations examined singly after adjustment for the
clinical covariates (age, sex, baseline eGFR, albuminuria and
HbA1c, calendar time).
Generation of a sparse panel from the original case–cohort
dataset Full details of the original case–control study are giv-
en elsewhere [6]. Data from that study were used to identify or
learn the best performing sparse panels of biomarkers from
ELISA- and Luminex-based methods and a panel from the
mass spectrometry-based method separately through the same
cross-validated forward selection approach used in the origi-
nal study.We used the R package nestfs (version 0.8.6: https://
CRAN.R-project.org/package=nestfs) where the variables are
selected based on the smallest false discovery rate computed
in an inner cross-validation and stopped the forward selection
for each platform at five biomarkers. Then we evaluated per-
formance of the selected panels containing only the first of
these five, then the first two, the first three, etc., up to five of
these biomarkers in the validation SDR, GoDARTS and
CARDS cohorts.
Predictive performance of sparse biomarker panels in the
three validation cohorts We then evaluated the performance
of the sparse panels of biomarkers generated on the original
case–control dataset on each of the cohorts. The increment in
prediction achieved by the panels was assessed when added to
the set of clinical covariates described above and also added to
a richer set of clinical covariates (age, sex, baseline eGFR,
albuminuria, HbA1c, calendar time, diabetes duration, systolic
and diastolic blood pressure, BMI, weighted average of his-
toric eGFR, insulin therapy and smoking status). For CARDS
samples we included a term for treatment allocation (atorva-
statin or placebo) but removed the weighted average of histor-
ic eGFR as it was not available. To assess the performance of
these biomarker panels in the new datasets, we used tenfold
cross-validation to control for overfitting and provide an esti-
mate of predictive performance on data not used to learn the
model coefficients. The area under the receiver operating char-
acteristic curve (AUROC) was evaluated by combining risk
prediction scores and outcomes in each person-time interval
over all test folds. We used the difference in test log-
likelihoods to evaluate the strength of evidence favouring
one model over another (see ESM Methods). To demonstrate
the role of biomarkers in selecting potential clinical trial par-
ticipants, we plotted the positive predictive value of the test
against the percentile of the risk score derived from the logistic
regression models with and without biomarkers. As a final
comparison step we further considered the performance ob-
tained by the original multiplatform panels on the three cohorts
against that for the sparse panels. All analyses were undertak-
en using R version 3.3.3 (https://www.R-project.org/) [12].
Results
Baseline characteristics of the validation cohorts Clinical
characteristics of the participants in the studies are shown in
Table 1. Baseline eGFR was similar in the SDR and Go-
DARTS cohorts (52.6 vs 53.4 ml min−1 [1.73 m]−2) and higher
in the CARDS participants (62.1 ml min−1 [1.73 m]−2). The
weighted average of prior eGFRs was higher for the Go-
DARTS (60.8 ml min−1 [1.73 m]−2) vs SDR (53.4 ml min−1
[1.73m]−2) cohort and albuminuria was slightly more common
in the former. Consistent with this, the SDR cohort showed a
more rapid loss of renal function than the GoDARTS cohort,
with a respective annual decrease in eGFR of 1.3 ml min−1
[1.73 m]−2 vs 0.5 ml min−1 [1.73 m]−2. CARDS selected par-
ticipants with no history of cardiovascular disease (CVD) but
at least one CVD risk factor (such as smoking, hypertension or
microvascular disease) whereas the other cohorts did not apply
these restrictions. Other than differences in baseline
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characteristics, calendar time of study and country, there are
differences in how samples were handled. While GoDARTS
and CARDS samples were stored at −80°C, SDR samples
were held principally at −20°C. GoDARTS samples were
stored for a shorter time than the SDR samples. Accordingly,
these cohorts allowed us to test the robustness of any biomark-
er panel performance across varying conditions. In total there
were 403 progression events across the three sample sets—118
in SDR, 192 in GoDARTS and 93 in CARDS.
Distribution of biomarkers across validation cohorts ESM
Table 1 shows the distribution of the 42 biomarkers included
in the analyses, showing that levels of some varied substan-
tially between these cohorts. For adrenomedullin and fibro-
blast growth factor 23 (FGF23), known to be sensitive to
sample handling and storage temperatures, >50% of samples
had concentrations below the detection threshold in SDR and
CARDS compared with <5% in the GoDARTS cohort. N-
terminal prohormone of brain natriuretic peptide (NT-
proBNP) also varied with storage temperature across the stud-
ies (213 pg/ml, 724 pg/ml and 33 pg/ml for SDR, GoDARTS
and CARDS, respectively). There was also a marked differ-
ence in the concentrations of glutamine and glutamic acid
between the SDR and GoDARTS cohorts, likely reflecting
conversion of glutamine to glutamic acid resulting in a higher
ratio of glutamic acid to glutamine at higher storage tempera-
tures [13, 14]. However, most other biomarkers, including
kidney injury molecule 1 (KIM-1), showed remarkable con-
sistency in range across the three cohorts.
Univariate associations of biomarkers with eGFR decline Of
the 42 biomarkers examined, 12 were significantly associated
with decline in eGFR in at least one study, after adjusting for
clinical covariates (Table 2). The biomarkers most strongly
associated with decline, evaluated singly, were similar across
the studies. Of these, beta 2 microglobulin (B2M), cystatin C,
IL-2 receptor α (IL2Ra), KIM-1 and Tamm–Horsfall urinary
glycoprotein reached the significance threshold in at least two
studies. B2M was strongly correlated with eGFR, cystatin C,
IL2Ra, TNF receptor 1, adrenomedullin and SDMA. In con-
trast, KIM-1 and high-sensitivity troponin Twere not strongly
correlated with any of the other measured biomarkers or clin-
ical covariates. When adjusting for a richer set of clinical
covariates, ADMA, SDMA and NT-proBNP were no longer
significantly associated with eGFR decline in any of the co-
horts (Fig. 1a–c).
The correlation coefficients for these biomarkers with each
other and with baseline eGFR are shown in Table 3.
Generation of a sparse panel from the original case–cohort
dataset As described above, we learned the best platform-
specific sets of biomarkers on the original sample set by using
forward selection on a given platform with the selection pro-
cess set to terminate at a maximum of five biomarkers. When
restricted only to the ELISA or Luminex biomarkers, the first
five biomarkers selected were B2M, KIM-1, myoglobin, NT-
proBNP and ferritin. Using only the mass spectrometry bio-
markers, the first five biomarkers selected were SDMA–
ADMA ratio, α1-antitrypsin 2, C16 acylcarnitine, proline
Table 1 Clinical characteristics of the SDR, GoDARTS and CARDS participant sample sets
Characteristic SDR (n = 227) GoDARTS (n = 430) CARDS (n = 183)
Age, years 68.6 (61.6, 75.5) 73.0 (68.0, 78.0) 64.6 (60.8, 69.3)
eGFR, ml min−1 [1.73 m]−2 52.6 (42.2, 58.5) 53.4 (43.3, 63.8) 62.1 (54.5, 68.7)
HbA1c, mmol/mol 61.2 (50.3, 74.9) 54.1 (46.5, 62.6) 58.5 (49.7, 71.6)
HbA1c, % 7.7 (6.8, 9.0) 7.1 (6.4, 7.9) 7.5 (6.7, 8.7)
BMI, kg/m2 29.0 (26.0, 32.6) 30.6 (27.1, 34.2) 29.0 (26.4, 31.2)
Diabetes duration, years 10.0 (3.0, 15.9) 7.9 (4.5, 13.0) 8.0 (4.0, 11.5)
Systolic blood pressure, mmHg 147.2 (143.7, 151.0) 143.0 (131.1, 155.5) 147.0 (138.0, 160.0)
Diastolic blood pressure, mmHg 79.6 (76.1, 81.5) 71.5 (65.0, 80.0) 82.5 (76.5, 90.0)
Weighted average of historic eGFR, ml min−1 [1.73 m]−2 53.4 (43.2, 61.3) 60.8 (50.6, 71.8) NA
Annualised eGFR slope, ml min−1 [1.73 m]−2 year−1 −1.3 (−2.8, 0.1) −0.5 (−1.9, 0.8) NA
Year at baseline 1997 (1997, 1998) 2005 (2005, 2007) 1999 (1998, 2000)
Follow-up duration, years 8.7 (4.8, 13.1) 7.1 (5.3, 8.8) 3.2 (2.9, 4.0)
Male sex 83 (36.6) 194 (45.1) 121 (66.1)
Albuminuria, yes 84 (37.0) 133 (30.9) 27 (14.8)
ACEi/ARB use NA 313 (72.8) 107 (58.5)
Insulin use 88 (38.8) 122 (28.4) 42 (23.0)
Current smoking 10 (4.4) 42 (9.8) 35 (19.1)
Data are median (interquartile range) or n (%)
ACEi, ACE inhibitor; ARB, angiotensin II receptor blocker
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and tryptophan. Using nested cross-validation, these panels
improved prediction in the original dataset beyond clinical
covariates from an AUROC (95% CI) of 0.706 (0.647,
0.764) to 0.846 (0.803, 0.889) for Luminex biomarkers and
to 0.806 (0.757, 0.854) for the mass spectrometry biomarkers.
Predictive performance of sparse biomarker panels in the
three validation cohorts In the validation sets from SDR,
GoDARTS and CARDS, the sparse Luminex panels consis-
tently significantly improved prediction in all sample sets on
top of clinical covariates, with most of the increment in predic-
tion obtained with the addition of the first two biomarkers,
B2M and KIM-1 (Table 4). As shown in Table 4, a combina-
tion of B2M and KIM-1 added to clinical covariates, including
baseline eGFR and albuminuria, modestly improved predic-
tion, increasing the area under the curve in the SDR, Go-
DARTS and CARDS by 0.079, 0.073 and 0.239, respectively.
In GoDARTS, but not SDR or CARDS, additional biomarkers
myoglobin and NT-proBNP gave a further increment in predic-
tion. The lower AUROC for the CARDS clinical covariates
only model can be explained by the fact that participants were
matched for age, sex and baseline eGFR so that these variables
cannot contribute to the AUROC. Substituting B2M with
cystatin C, with which it is highly correlated, achieved a similar
increment in prediction in GoDARTS but not in SDR or
CARDS (ESMTable 2). In addition, on top of amore extensive
set of clinical covariates, the Luminex panel showed a small
increment in prediction (ESM Table 3). However, the sparse
mass spectrometry-specific panel did not perform well in either
the validation SDR or GoDARTS in which it was measured.
Comparison of performance with the larger multiplatform
panels derived in [6] is reported in ESM Table 4.
The increments in AUROC here are modest. To consider
their utility, the role of biomarkers in selection of individuals
for entry into a clinical trial can be shown by looking at the
predicted event rate enrichment plots (Fig. 2a–c). These plots
display the positive predicted value (y-axis) achieved over the
percentile of patients sorted by predicted risk score (x-axis).
Without any risk stratification, the expected cumulative inci-
dence of a progression event was set to 12%, consistent with
what was done in [6]. However, by looking at a subset of
individuals with the largest risk scores, a model that included
B2M and KIM-1 could yield enrichment for events that would
be useful in the context of selection of individuals to be invited
into clinical trials. For example, looking at the GoDARTS
results (Fig. 2b), selecting people in the top 10% for the bio-
markers would enrich the expected event rate from 12% to
about 24% (i.e. a doubling in the expected event rate). Across
the range of percentiles of risk score, enrichment can be seen
for all three studies—the small sample size at the most ex-
treme percentile of 10% showing overlapping lines for
CARDS due to small sample size in that part of the range.
Discussion
We have shown that it is possible to significantly improve
prediction of eGFR decline using just two biomarkers—
B2M and KIM-1—in combination and that the prediction
achieved is similar to that seen in our test cohorts with the
Table 2 Associations for the 12 biomarkers out of 42 that showed significant univariate association with rapid decline in eGFR
Biomarker Method SDR GoDARTS CARDS
OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value
Adrenomedullin (ng/ml)a Luminex – – 1.47 (1.26, 1.72) 1.11 × 10−6 1.58 (1.09, 2.34) 1.90 × 10−2
ADMA (nmol/l) MSMS 1.46 (1.18, 1.81) 4.60 × 10−4 1.04 (0.90, 1.21) 5.97 × 10−1 Not measured –
B2M (μg/ml) Luminex 1.98 (1.54, 2.56) 1.28 × 10−7 1.59 (1.34, 1.89) 1.37 × 10−7 2.92 (1.79, 5.06) 4.93 × 10−5
Cystatin C (ng/ml) Luminex 1.83 (1.40, 2.38) 8.08 × 10−6 1.64 (1.36, 1.97) 2.03 × 10−7 1.84 (1.22, 2.84) 4.31 × 10−3
Fibroblast growth factor 23 (ng/ml) Luminex 1.12 (0.89, 1.41) 3.20 × 10−1 1.37 (1.17, 1.59) 7.67 × 10−5 1.51 (1.07, 2.15) 2.00 × 10−2
IL-2Ra (pg/ml) Luminex 1.62 (1.28, 2.07) 8.00 × 10−5 1.20 (1.02, 1.41) 2.38 × 10−2 2.06 (1.42, 3.11) 2.89 × 10−4
KIM-1 (ng/ml) Luminex 1.66 (1.32, 2.09) 1.85 × 10−5 1.48 (1.25, 1.76) 6.65 × 10−6 1.94 (1.37, 2.81) 2.52 × 10−4
NT-ProBNP (pg/ml) Luminex 1.18 (0.96, 1.45) 1.10 × 10−1 1.44 (1.21, 1.71) 3.73 × 10−5 1.26 (0.88, 1.82) 2.15 × 10−1
SDMA (nmol/l) MSMS 1.80 (1.33, 2.43) 1.24 × 10−4 1.20 (0.98, 1.47) 7.51 × 10−2 Not measured –
Tamm–Horsfall urinary glycoprotein
(μg/ml)
Luminex 0.64 (0.50, 0.83) 7.09 × 10−4 0.65 (0.53, 0.78) 1.20 × 10−5 0.75 (0.54, 1.04) 8.61 × 10−2
Troponin T (high sensitivity) (pg/ml) ELISA 1.66 (1.32, 2.11) 2.33 × 10−5 1.05 (0.88, 1.26) 5.63 × 10−1 Not measured –
TNF receptor 1 (pg/ml) Luminex 1.63 (1.26, 2.13) 2.30 × 10−4 1.32 (1.11, 1.56) 1.69 × 10−3 1.85 (1.26, 2.82) 2.62 × 10−3
Associations after adjusting for clinical covariates (age, sex, baseline eGFR, albuminuria, HbA1c, calendar time) are shown; CARDSmodels also include
a term for treatment allocation
a For adrenomedullin, >90% samples were below the detection threshold in SDR
MSMS, tandem mass spectrometry
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previously described larger biomarker panels selected using a
discovery cohort [6]. B2M was strongly correlated with a
number of other biomarkers, including cystatin C, but substi-
tution with cystatin C did not in general produce the same
performance. On the other hand, KIM-1 was not strongly
correlated with any of the clinical covariates or other bio-
markers we measured.
A range of potentially useful biomarkers of renal disease
progression in diabetes have been identified in serum, plasma
[2–4], [15] and urine [16, 17] but many studies tested only a
small number of biomarkers and few have explored biomarker
combinations. Given the pathophysiological complexity of
diabetic kidney disease, it is unlikely that one single biomark-
er can predict its progression [18]. Very few have explored
consistency of prediction across cohorts with varying charac-
teristics or under varying sample handling conditions. Here,
we have combined the measurement of a wide range of bio-
markers in samples from three distinct studies to identify the
biomarkers that improve prediction of declining eGFR and
thus may be best suited as biomarkers for general use. We
have also used logistical considerations, such as keeping the
required number of biomarkers low and the desirability for all
biomarkers to exist on a single platform, to limit our biomark-
er selections. This provides a combination of biomarkers that,
while it might not maximise prediction in any sample set,
significantly improves prediction in all sample sets. Our aim
was to identify a non-redundant robust panel of markers that
may be of practical relevance, rather than to identify all pos-
sible markers associated with progression.
Both B2M and KIM-1 have been widely studied as poten-
tial renal biomarkers, though not considered in combination.
B2M is fully filtered at the glomerulus and then almost
completely reabsorbed in the proximal tubule. In healthy con-
ditions its production is constant, thus making it suitable as a
surrogate for eGFR [19, 20]. However, B2M serum levels are
elevated in inflammatory conditions, limiting its use as a
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Fig. 1 Volcano plots of biomarkers with decline in renal function adjust-
ed for a rich set of clinical covariates in the SDR (a), GoDARTS (b) and
CARDS (c) cohorts. The x-axes show the OR expressed on a natural
logarithm (loge) scale; the y-axes depict the statistical significance on a
log10 scale. Red circles correspond to biomarkers significantly associated
with decline in eGFR (p < 0.0012). Clinical covariates for SDR and Go-
DARTS cohorts were age, sex, baseline eGFR, albuminuria, HbA1c, cal-
endar time, diabetes duration, systolic and diastolic blood pressure, BMI,
weighted average of historic eGFR, insulin therapy and smoking status.
Clinical covariates for CARDS participants were age, sex, baseline
eGFR, albuminuria, HbA1c, calendar time, diabetes duration, systolic
and diastolic blood pressure, BMI, insulin therapy, smoking status and
treatment allocation. ADM, adrenomedullin; CysC, cystatin C; FGF23,
fibroblast growth factor 23; THP, Tamm–Horsfall urinary glycoprotein;
TNFR1, TNF receptor 1; TnT, high-sensitivity troponin T
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Table 3 Correlation matrix for leading predictive biomarkers for rapid eGFR decline in SDR, GoDARTS and CARDS samples
Biomarker ADM ADMA B2M CysC FGF23 FRTN IL2Ra KIM-1 MB NT-proBNP SDMA THP TnT TNFR1
eGFR
SDR – −0.24 −0.66 −0.66 −0.44 0.10 −0.51 −0.30 −0.55 −0.35 −0.70 0.42 −0.44 −0.64
GoDARTS −0.49 −0.21 −0.64 −0.67 −0.27 −0.07 −0.38 −0.14 −0.39 −0.33 −0.64 0.41 −0.33 −0.48
CARDS 0.03 – −0.49 −0.57 −0.05 0.10 −0.37 −0.20 −0.31 −0.13 – 0.12 – −0.48
ADMa
Go-DARTS 1 0.26 0.70 0.69 0.52 −0.03 0.52 0.21 0.27 0.54 0.48 −0.47 0.42 0.51
CARDS 1 – 0.38 0.05 0.62 0.01 0.25 0.13 −0.09 0.67 – −0.04 – 0.10
ADMAb
SDR 1 0.35 0.41 0.19 −0.09 0.27 0.07 0.07 0.16 0.48 −0.24 0.19 0.34
Go-DARTS 1 0.31 0.26 0.15 0.04 0.30 0.01 0.06 0.22 0.37 −0.13 0.13 0.18
B2M
SDR 1 0.89 0.46 0.00 0.62 0.43 0.52 0.43 0.69 −0.49 0.56 0.70
Go-DARTS 1 0.87 0.38 0.05 0.62 0.27 0.34 0.41 0.61 −0.54 0.42 0.65
CARDS 1 0.67 0.36 0.07 0.61 0.25 0.27 0.45 – −0.27 – 0.57
CysC
SDR 1 0.48 0.00 0.59 0.42 0.60 0.38 0.71 −0.48 0.53 0.69
Go-DARTS 1 0.37 0.12 0.56 0.25 0.41 0.41 0.60 −0.51 0.42 0.66
CARDS 1 0.15 0.06 0.52 0.18 0.42 0.17 – −0.21 – 0.46
FGF23
SDR 1 −0.13 0.28 0.23 0.32 0.37 0.39 −0.29 0.33 0.43
Go-DARTS 1 −0.23 0.29 0.20 0.10 0.37 0.24 −0.23 0.21 0.31
CARDS 1 −0.17 0.24 0.25 −0.01 0.53 – −0.02 – 0.19
FRTN
SDR 1 0.01 0.27 0.13 −0.04 0.03 0.03 0.13 −0.04
Go-DARTS 1 0.01 −0.05 0.18 −0.11 0.08 0.04 0.02 0.03
CARDS 1 −0.08 0.00 0.21 0.01 – 0.00 – −0.01
IL2Ra
SDR 1 0.40 0.35 0.18 0.43 −0.24 0.33 0.65
Go-DARTS 1 0.24 0.24 0.26 0.41 −0.30 0.25 0.60
CARDS 1 0.28 0.09 0.30 – −0.26 – 0.51
KIM-1
SDR 1 0.31 0.22 0.31 −0.18 0.46 0.42
G-DARTS 1 0.05 0.14 0.12 −0.15 0.14 0.22
CARDS 1 0.13 0.11 – −0.09 – 0.36
MB
SDR 1 0.20 0.56 −0.29 0.59 0.47
GoDARTS 1 0.20 0.35 −0.20 0.40 0.26
CARDS 1 0.13 – −0.13 – 0.18
NT-proBNP
SDR 1 0.37 −0.27 0.49 0.27
GoDARTS 1 0.39 −0.30 0.41 0.30
CARDS 1 – −0.08 – 0.12
SDMAb
SDR 1 −0.47 0.56 0.61
Go-DARTS 1 −0.43 0.42 0.45
THP
SDR 1 −0.38 −0.40
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surrogate [21–23]. There are, however, many reports identify-
ing its potential role as a biomarker for both diabetic kidney
disease [24] and end-stage renal disease [25, 26] as well as for
CVD [24, 25] and mortality [25, 26]. KIM-1 is also a mem-
brane protein, expressed on the apical membrane of kidney
proximal tubule cells. It is a urinary marker of kidney injury
and circulating KIM-1 is raised in patients with acute kidney
injury [4]. Urinary KIM-1 has shown mixed results as a prog-
nostic biomarker in diabetic kidney disease [27, 28] but glo-
merular KIM-1 expression is increased in animal models of
diabetes [28], associated with elevated plasma levels [29].
Serum KIM-1 also predicts eGFR decline and incidence of
end-stage renal disease in type 1 diabetes [4] and is associated
with microalbuminuria in type 1 diabetes, suggesting that it
may have a role in identifying individuals at risk in early
stages of renal disease [30]. B2M is principally a biomarker
of filtration while KIM-1 is not, possibly explaining why they
work well together in combination. NT-proBNP was also
found to add some benefit in the CARDS and GoDARTS
cohorts when added to B2M and KIM-1. NT-proBNP is a
biomarker for heart failure [31] and may also be a good bio-
marker for CVD outcomes [32, 33]. However, it is also
cleared renally and levels rise as renal function declines
[34]. In addition, as noted here, NT-proBNP is not robust to
variation in sample handling conditions.
The current study has a number of strengths. By including
samples from three studies we identified biomarkers that per-
formed well across populations and studies. By measuring
many biomarkers simultaneously, we were able to identify
those biomarkers that potentially provide the same informa-
tion (i.e. B2M and cystatin C) by considering the correlation
matrix as well as those that seem to provide additional novel
information, such as KIM-1.
Our study illustrates that even when cross-validation is
used to avoid overfitting when finding a predictive panel, as
we did in defining the large panels in our previous report, this
does not guarantee generalisability to other settings.
Furthermore, maximising prediction is not the only goal of
biomarker discovery. Our study highlights practical consider-
ations such as limiting the panel to a specific assay method
and choosing biomarkers that are robust to the sorts of con-
ditions in which they would really be measured. Furthermore,
we note that the choice of prediction metric is a complex
issue in biomarker studies. Here, not only have we presented
the conventional increment in AUROC but also we have
shown how the performance increment applies in the context
of trial enrichment. An important point is that even modest
increments in prediction, as found here, can nonetheless be
very useful for enriching event rates in trials.
Our study has focussed on the prediction of serum
creatinine-based eGFR decline. Of course, there has been ex-
tensive work evaluating the usefulness of other filtration
biomarker-based equations including cystatin C and B2M,
and their combination, for improving the accuracy of estima-
tion of the underlying true GFR [35, 36]. The development
and use of a biomarker panel-based eGFR has recently been
advocated for both clinical and trial use [37]. While there are
sound arguments and increasing data to support this, we en-
visage that it will be some time before this is widely approved
and adopted as a trial endpoint. In the meantime our data
suggest that B2M along with KIM-1 might at least be used
for risk stratification into trials using creatinine-based eGFR
as part of the endpoint definition.
The study also has limitations. Since there are differ-
ences in entry criteria and definition of caseness between
our discovery cohort and the cohort sets studied here, we
cannot consider this strictly as a replication study. The
original biomarker panels were identified based on their
power to predict a ≥40% decline in eGFR over a maxi-
mum follow-up of 3.5 years whereas in the current study
we look at a decline of ≥20% over a longer follow-up
period. Thus, we are applying our biomarkers to a much
Table 3 (continued)
Biomarker ADM ADMA B2M CysC FGF23 FRTN IL2Ra KIM-1 MB NT-proBNP SDMA THP TnT TNFR1
GoDARTS 1 −0.40 −0.39
CARDS 1 – −0.29
TnTb
SDR 1 0.50
Go-DARTS 1 0.28
Data are Pearson correlation coefficients for 12 biomarkers shown to be significantly associated in any of the cohorts as well as two additional biomarkers
(myoglobin and ferritin) that appear in the sparse panel of Luminex biomarkers
a For adrenomedullin, >90% samples were below the detection threshold in SDR
bADMA, SDMA and TnTwere not measured in CARDS
ADM, adrenomedullin; CysC, cystatin C; FGF23, fibroblast growth factor 23; FRTN, ferritin; MB, myoglobin; THP, Tamm–Horsfall urinary glyco-
protein; TnT, high-sensitivity troponin T; TNFR1, TNF receptor 1
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less severe phenotype than previously. Part of the rationale
for this study was to explore the use of biomarkers for
less extreme phenotypes. We expected that this might di-
minish associations between biomarkers and outcome.
However, we have confirmed that the biomarkers that pre-
dict more severe decline in renal function can also predict
less severe decline and may be useful at earlier stages of
kidney disease. Since a 20% drop in eGFR will be a
noisier outcome measure than a 40% drop, this means that
we would have had less power to detect biomarker asso-
ciations. Nevertheless, it would not increase the level of
false associations and our strict cross-validation techniques
further protect against overfitting. In the GoDARTS and
CARDS sample sets in this study the clinical covariates
were poor predictors compared with the original discovery
case–control study and SDR cohort. However, despite this,
addition of the biomarkers increased the AUROC to a
similar degree in the SDR and GoDARTS cohorts. We
did not have the mass spectrometry biomarkers available
in the CARDS samples.
We have shown that the combination of B2M and
KIM-1, measured in serum, in addition to clinical covari-
ates, significantly improves prediction of renal function
decline in type 2 diabetes on top of clinical data. Use of
a larger multiplatform biomarker panel did not consistently
improve prediction further.
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Fig. 2 Expected cumulative
incidence from the observed 12%
(horizontal dashed line) if a trial
subsampled the top percentile of
possible study entrants according
to their risk score for a model
containing only clinical
covariates (red lines) or a model
augmented with B2M and KIM-1
(blue lines), for SDR (a), Go-
DARTS (b) and CARDS (c).
Clinical covariates are age, sex,
baseline eGFR, albuminuria,
HbA1c and calendar time.
CARDS models also include a
term for treatment allocation
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